108 related articles for article (PubMed ID: 7078802)
1. [Immunological aspects in the treatment of malignant melanoma].
Cascinelli N; Vaglini M; Rovini D; Orefice S; Marolda R; Veronesi U
Minerva Med; 1982 Apr; 73(18):1233-40. PubMed ID: 7078802
[No Abstract] [Full Text] [Related]
2. [Intralymphatic administration of BCG-CWS in advanced malignant melanoma].
Mannami T; Matsumi A; Ichikawa J; Kagawa S; Orita K; Motoi M
Gan To Kagaku Ryoho; 1982 Jan; 9(1):85-90. PubMed ID: 7184364
[TBL] [Abstract][Full Text] [Related]
3. Current concepts in the management of malignant melanoma.
Lichtenfeld JL
Am J Med Sci; 1976; 272(2):185-95. PubMed ID: 1008080
[No Abstract] [Full Text] [Related]
4. [Results in the use of immunochemotherapy in patients with cutaneous malignant melanoma].
Calbo L; Gorgone S; Palmeri R; Salibra M; Melita P
Chir Ital; 1983 Aug; 35(4):519-25. PubMed ID: 6680859
[TBL] [Abstract][Full Text] [Related]
5. [Experience with adjuvant chemoimmunotherapy with DTIC and BCG in malignant melanoma (author's transl)].
Pullmann H; Muth M
Z Hautkr; 1982 Feb; 57(4):294-7. PubMed ID: 7080583
[No Abstract] [Full Text] [Related]
6. [Results of immunochemotherapy in malignant melanoma].
Duchková H; Richter J; Kubíková M; Peska J; Ragan J; Vohryzková E; Hrivnáková J; Kvasnicka J
Cesk Dermatol; 1980 Aug; 55(4):277-80. PubMed ID: 7407970
[No Abstract] [Full Text] [Related]
7. Letter: Chemoimmunotherapy of malignant melanoma.
N Engl J Med; 1975 Jan; 292(3):159-60. PubMed ID: 1196343
[No Abstract] [Full Text] [Related]
8. [Multiple BCG-induced ulcers after subcutaneous vaccination in the framework of immunochemotherapy in malignant melanoma].
Korting HC; Strasser S; Konz B
Hautarzt; 1988 Mar; 39(3):170-3. PubMed ID: 3378889
[TBL] [Abstract][Full Text] [Related]
9. Endolymphatic BCG therapy in the rabbit VX2 tumor.
Edwards JM; O'Donnell TF; Johnson H; Rutt D; Kinmonth JB
Surg Forum; 1975; 26():147-9. PubMed ID: 1216093
[No Abstract] [Full Text] [Related]
10. [Adjuvant chemotherapy in malignant melanoma after pretherapeutic sensitivity testing].
Zaumseil RP; Wohlrab W; Fiedler H; Wozniak KD
Folia Haematol Int Mag Klin Morphol Blutforsch; 1981; 108(5):721-4. PubMed ID: 6172340
[No Abstract] [Full Text] [Related]
11. Immunotherapy for recurrent malignant melanoma: efficacy of BCG in prolonging the postoperative disease-free interval and survival.
Gutterman JU; Richman SP; McBride CM; Burgess MA; Bartold SL; Kennedy A; Gehan EA; Mavligit G; Hersh EM
Recent Results Cancer Res; 1978; 68():359-62. PubMed ID: 752870
[No Abstract] [Full Text] [Related]
12. Intralymphatic and regional surgical adjuvant immunotherapy in high-risk melanoma of the extremities.
Ariyan S; Kirkwood JM; Mitchell MS; Nordlund JJ; Lerner AB; Papac RJ
Surgery; 1982 Sep; 92(3):459-63. PubMed ID: 7112396
[TBL] [Abstract][Full Text] [Related]
13. Results of adjuvant BCG immunotherapy in malignant melanoma.
Wätzig V; Knopf B
Arch Geschwulstforsch; 1981; 51(6):493-6. PubMed ID: 7332442
[TBL] [Abstract][Full Text] [Related]
14. [Recent controlled studies on the therapy of malignant melanoma].
Canavese G; Margarino G
Minerva Med; 1982 Dec; 73(48):3458-60. PubMed ID: 6757800
[No Abstract] [Full Text] [Related]
15. [Malignant melanoma].
Minerva Med; 1981 Apr; 72(17):1095-8. PubMed ID: 7231768
[No Abstract] [Full Text] [Related]
16. Adjuvant immunotherapy of malignant melanoma.
Aranha GV; McKhann CF; Grage TB; Gunnarsson A; Simmons RL
Cancer; 1979 Apr; 43(4):1297-303. PubMed ID: 445331
[TBL] [Abstract][Full Text] [Related]
17. Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Eastern Oncology Group.
Agarwala SS; Neuberg D; Park Y; Kirkwood JM
Cancer; 2004 Apr; 100(8):1692-8. PubMed ID: 15073858
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant therapy in malignant melanoma: a trial of immunotherapy. chemotherapy, and combined treatment.
Kaufman SD; Cosimi AB; Wood WC; Carey RW
Recent Results Cancer Res; 1978; 68():380-6. PubMed ID: 752874
[No Abstract] [Full Text] [Related]
19. Experiences in adjuvant immunotherapy of melanoma with BCG substrain Jena S 4.
Wätzig V; Zureck A
Dev Biol Stand; 1986; 58 ( Pt A)():461-4. PubMed ID: 3297877
[No Abstract] [Full Text] [Related]
20. Endolymphatic isotope and BCG in the management of malignant melanoma.
Edwards JM; Pheils PJ
Aust N Z J Surg; 1978 Feb; 48(1):40-8. PubMed ID: 276347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
